Default company panoramic image
A08f357a 26a8 4d11 bc57 720dea161b9f

ReBA Therapeutics Inc

The respiratory bridge adaptor improves the efficiency and precision of delivering aerosolized medications for patients while on a mechanical ventilator.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded June 2018
  • Employees 3
  • Incorporation Type C-corp
  • Website rebatx.com

Company Summary

ReBA Therapeutics is dedicated to advancing the Temple University patent for the "respiratory bridge adaptor" (RBA) from the concept through to pre-commercialization. Our Development Plan will require $650,000 over 18 months and the US Market potential is approximately $60 M (50% of the global market). Industry "comps" indicate a valuation of $20 M upon completion of product development, yielding an ROI of 14X.

Advisors